Understanding how tumors block immune cells to improve cancer treatment
Breaching the Tumor-Immune Mechanical Barrier for Optimal Antitumor Immunity
['FUNDING_CAREER'] · MASSACHUSETTS GENERAL HOSPITAL · NIH-11012296
This study is looking at how tumors block immune cells from fighting cancer, especially focusing on a molecule called TROP2 that is related to aggressive breast cancer, with the hope of finding new ways to help the immune system better attack tumors and improve treatment options for patients.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MASSACHUSETTS GENERAL HOSPITAL (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11012296 on ClinicalTrials.gov |
What this research studies
This research investigates the mechanical barriers that tumors create to prevent immune cells from infiltrating and attacking cancer. By focusing on a specific molecule called TROP2, which is linked to aggressive breast cancer, the research aims to uncover how these barriers work and how they can be overcome. The approach involves studying the interactions between tumor cells and immune cells, with the goal of designing therapies that can break down these barriers and enhance the body's immune response against tumors. Patients may benefit from new treatment strategies that improve the effectiveness of existing cancer therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with aggressive forms of breast cancer, particularly those with high levels of TROP2 expression.
Not a fit: Patients with non-cancerous conditions or those whose tumors do not express TROP2 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments by enhancing the immune system's ability to fight tumors.
How similar studies have performed: Previous research has shown promise in targeting similar mechanical barriers in cancer, suggesting that this approach could be effective.
Where this research is happening
BOSTON, UNITED STATES
- MASSACHUSETTS GENERAL HOSPITAL — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WU, BOGANG — MASSACHUSETTS GENERAL HOSPITAL
- Study coordinator: WU, BOGANG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapeutic, anti-cancer treatment